Investigating new natural compounds for treating high grade serous ovarian cancer
Official title: Pharmacological Potential of Combined Translation and Autophagy Inhibition in High Grade Serous Ovarian Cancer
Funded at University of Illinois at Chicago · NIH-10946931 · Data updated 2026-11-12
This study is looking at two natural compounds that might help treat high grade serous ovarian cancer, which is a tough type of cancer to beat, and it aims to find out if these compounds can safely help kill cancer cells and improve treatment options for patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $120,972 |
| NIH project number | 1K99GM155616-01 |
| Project ID | NIH-10946931 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with high grade serous ovarian cancer, particularly those who have not responded well to existing therapies.
✕Less likely to help
Patients with other types of ovarian cancer or those who are not diagnosed with cancer may not benefit from this research.
What this research studies
This research focuses on high grade serous ovarian cancer, the most lethal form of ovarian cancer, which often becomes resistant to current treatments. The study aims to evaluate the effectiveness of two natural compounds, didesmethylrocaglamide and phyllanthusmin34, which have shown promise in inducing cancer cell death through different mechanisms. By understanding how these compounds work, the research seeks to develop new therapeutic strategies that could improve outcomes for patients with this aggressive cancer. Patients may be involved in trials to assess the safety and efficacy of these treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients suffering from high grade serous ovarian cancer.
How similar studies have gone: Other research has shown promise in using natural compounds for cancer treatment, indicating potential for success with this approach.
Where this research is happening
-
University of Illinois at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Kaweesa, Elizabeth — University of Illinois at Chicago
- Study coordinator: Kaweesa, Elizabeth
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.